Efficacy
DISEASE PROGRESSION
The study met the pre-specified primary endpoint, with a 6-month PFS rate of 88.6% (95% confidence interval (CI) 75.4–96.2). At the data cutoff point, 19 patients showed disease progression after a median of 13.7 months (IQR 8.6–20.8). Secondary endpoints were also investigated. Overall, the median PFS was 22.4 months (20.4–∞) (Fig. 